Left ventricular sensing in cardiac resynchronization devices—opportunities and pitfalls for device programming
Introduction Some cardiac resynchronization therapy (CRT) device manufacturers (Biotronik, Germany; Boston Scientific, United States) have implemented left ventricular (LV) sensing functionality to prevent pacing into the vulnerable phase. Physicians are only partially aware of programming pitfalls...
Saved in:
Published in | Journal of cardiovascular electrophysiology Vol. 30; no. 8; pp. 1352 - 1361 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.08.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Introduction
Some cardiac resynchronization therapy (CRT) device manufacturers (Biotronik, Germany; Boston Scientific, United States) have implemented left ventricular (LV) sensing functionality to prevent pacing into the vulnerable phase. Physicians are only partially aware of programming pitfalls related to LV sensing and general programming advice is lacking.
Methods and Results
We provide an illustrative case–series‐based review of the variety of potential problems with LV sensing. LV sensing may inappropriately impair CRT delivery due to LV‐sensing issues or improper device programming. This can cause beat‐wise loss of resynchronization but also ongoing desynchronization. On the other hand, LV sensing provides additional diagnostic information, which may reveal intermittent problems of the LV lead such as capture loss.
We summarize the available evidence to provide manufacturer‐specific recommendations on device programming and troubleshooting for daily clinical practice.
Conclusion
CRT devices with LV sensing may suffer from impaired resynchronization due to programming pitfalls. If LV sensing is active (nominal setting in Biotronik and Boston Scientific devices), careful lookout for related problems and resynchronization percentage is required. Optimization is mandatory and even deactivation of LV sensing may have to be considered. |
---|---|
Bibliography: | Swiss Heart Rhythm Foundation (fellowship to Dr. Haeberlin) has received travel and educational grants from Medtronic and Philips/Spectranetics and was a speaker for Abbott. Dr. Ritter has been a consultant for Microport and speaker for Medtronic. Other authors: No disclosures. Disclosures ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
ISSN: | 1045-3873 1540-8167 |
DOI: | 10.1111/jce.14039 |